Skip to main content
SUMO valor

Nano-radiopharmaceuticals against glioblastoma, the most aggressive brain tumour

Glioblastoma is one of the most aggressive brain cancers, with an average survival of less than one year. Advances in the diagnosis and treatment of this type of tumour are, to date, not very encouraging. 

The USC CiMUS groups led by Pablo Aguiar and María José Alonso plan to develop a new generation of radiopharmaceuticals capable of reaching the brain and, once there, targeting brain tumour cells, performing the dual function of early diagnosis and treatment. 

To this end, the researchers are based on a strategy that makes use of nanotechnology to produce nano-radiopharmaceuticals capable of crossing the haematoencephalic barrier, one of the most resistant barriers in our body, and, finally, of acting with high precision on the brain tumour. 

Progress in this line of research could bring about a paradigm shift in the treatment of glioblastoma and other cancers that are difficult to diagnose, and significantly improve the quality of life and life expectancy.

 
Entity
Universidade de Santiago de Compostela
Donation deadline